Reem ElSheikh, Sairi Zhang, Mohammad Z Siddiqui, Muhammad Z Chauhan, Ahmed B Sallam, Sami H Uwaydat
{"title":"玻璃体切除手术中接受地塞米松植入的糖尿病眼术后纤维蛋白样综合征的发生率。","authors":"Reem ElSheikh, Sairi Zhang, Mohammad Z Siddiqui, Muhammad Z Chauhan, Ahmed B Sallam, Sami H Uwaydat","doi":"10.2147/OPTH.S536499","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The dexamethasone implant (DEX) and pars plana vitrectomy (PPV) are both used to treat diabetic retinopathy. A rare complication of vitrectomy is post-operative fibrinoid syndrome (POFS). We report the incidence of POFS when PPV is combined with DEX injection in diabetic eyes.</p><p><strong>Methods: </strong>One hundred and five eyes of patients with diabetic retinopathy undergoing concurrent PPV and DEX were retrospectively analyzed.</p><p><strong>Results: </strong>Mean BCVA improved from 1.06 logMAR to 0.78 (p=0.05) at final follow-up. Mean CST was found to have a statistically insignificant decrease from 360 ± 154 µm to 314 ± 99 µm at final visit (p=0.13). Four eyes (3.8%) developed POFS. No major surgical complications were encountered.</p><p><strong>Conclusion: </strong>Combining PPV with DEX is safe and effective in patients with diabetic retinopathy. Our results showed an improvement in mean BCVA and a decrease in CST. The incidence of POFS was 3.8%, which is not significantly different from previously published data in 1982.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3567-3572"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495912/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Incidence of Post-Operative Fibrinoid Syndrome in Diabetic Eyes Receiving a Dexamethasone Implant During Pars Plana Vitrectomy Surgery.\",\"authors\":\"Reem ElSheikh, Sairi Zhang, Mohammad Z Siddiqui, Muhammad Z Chauhan, Ahmed B Sallam, Sami H Uwaydat\",\"doi\":\"10.2147/OPTH.S536499\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The dexamethasone implant (DEX) and pars plana vitrectomy (PPV) are both used to treat diabetic retinopathy. A rare complication of vitrectomy is post-operative fibrinoid syndrome (POFS). We report the incidence of POFS when PPV is combined with DEX injection in diabetic eyes.</p><p><strong>Methods: </strong>One hundred and five eyes of patients with diabetic retinopathy undergoing concurrent PPV and DEX were retrospectively analyzed.</p><p><strong>Results: </strong>Mean BCVA improved from 1.06 logMAR to 0.78 (p=0.05) at final follow-up. Mean CST was found to have a statistically insignificant decrease from 360 ± 154 µm to 314 ± 99 µm at final visit (p=0.13). Four eyes (3.8%) developed POFS. No major surgical complications were encountered.</p><p><strong>Conclusion: </strong>Combining PPV with DEX is safe and effective in patients with diabetic retinopathy. Our results showed an improvement in mean BCVA and a decrease in CST. The incidence of POFS was 3.8%, which is not significantly different from previously published data in 1982.</p>\",\"PeriodicalId\":93945,\"journal\":{\"name\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"volume\":\"19 \",\"pages\":\"3567-3572\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495912/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/OPTH.S536499\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S536499","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
The Incidence of Post-Operative Fibrinoid Syndrome in Diabetic Eyes Receiving a Dexamethasone Implant During Pars Plana Vitrectomy Surgery.
Introduction: The dexamethasone implant (DEX) and pars plana vitrectomy (PPV) are both used to treat diabetic retinopathy. A rare complication of vitrectomy is post-operative fibrinoid syndrome (POFS). We report the incidence of POFS when PPV is combined with DEX injection in diabetic eyes.
Methods: One hundred and five eyes of patients with diabetic retinopathy undergoing concurrent PPV and DEX were retrospectively analyzed.
Results: Mean BCVA improved from 1.06 logMAR to 0.78 (p=0.05) at final follow-up. Mean CST was found to have a statistically insignificant decrease from 360 ± 154 µm to 314 ± 99 µm at final visit (p=0.13). Four eyes (3.8%) developed POFS. No major surgical complications were encountered.
Conclusion: Combining PPV with DEX is safe and effective in patients with diabetic retinopathy. Our results showed an improvement in mean BCVA and a decrease in CST. The incidence of POFS was 3.8%, which is not significantly different from previously published data in 1982.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
